medigraphic.com
Instituto Nacional de Salud Pública

2016, Número 2

<< Anterior Siguiente >>

salud publica mex 2016; 58 (2)


Propuestas para la prevención de cáncer de pulmón en el sistema de salud en México

Arrieta O, López-Mejía M, Macedo-Pérez EO, Corona-Cruz JF

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 274-278
Archivo PDF: 203.56 Kb.


RESUMEN

El manejo del cáncer de pulmón es un reto que tiene como objetivo una supervivencia global significativa que se vea rodeada de una buena calidad de vida. Si se considera que el tabaquismo está asociado hasta con 71% de las muertes por cáncer, la primera política que debe establecerse es la de proporcionar información sobre el cáncer de pulmón, factores de riesgo, factores de protección y datos de alarma mediante una estrategia de salud de línea de vida, además del establecimiento de un método de tamizaje efectivo que permita un diagnóstico temprano. Después del diagnóstico, debe realizarse una genotipificación para identificar mutaciones sensibles y para proporcionar un tratamiento personalizado al paciente. Las políticas del sistema de salud deben incluir información para que la población incida en su salud y también se puedan realizar diagnósticos tempranos que permitan una mayor supervivencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brambilla E, Travis WD. Lung cancer. In: World Cancer Report, Stewart BW, Wild CP (Eds). Lyon. World Health Organization, 2014.

  2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123(1 Suppl):21S-49S.

  3. Organization WH. Cancer Fact sheet N°297. 2015 [accessed 2015 February]. Available at: http://www.who.int/mediacentre/factsheets/ fs297/en/

  4. Herrera-Portugal C, Franco-Sánchez G, Pelayes-Cruz M, Schlottfeldt- Trujillo Y, Pérez-Solís BL. Daño al ADN en mujeres expuestas al humo de la leña en Chiapas, México. Acta Toxicol Argent 2009;17(2):56-61.

  5. Arrieta O, Villarreal-Garza C, Martinez-Barrera L, Morales M, Dorantes- Gallareta Y, Pena-Curiel O, et al. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. BMC cancer 2013;13:254.

  6. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93(7):825-833.

  7. Naff JL, Cote ML, Wenzlaff AS, Schwartz AG. Racial differences in cancer risk among relatives of patients with early onset lung cancer. Chest 2007;131(5):1289-1294.

  8. Arrieta O, Ramirez-Tirado LA, Baez-Saldana R, Pena-Curiel O, Soca- Chafre G, Macedo-Perez EO. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”. Lung cancer 2015;90(2):161-166.

  9. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Thorac oncol 2015;10(5):838-843.

  10. Reynales-Shigematsu LM, Guerrero-López CM, Lazcano-Ponce E, Villatoro-Velázquez JA, Medina-Mora ME, Fleiz-Bautista C, et al. Encuesta Nacional de Adicciones 2011: Reporte de Tabaco. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz; Instituto Nacional de Salud Pública; Secretaría de Salud. México DF, México: INPRFM, 2012.

  11. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321(7257):323-329.

  12. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163(12):1475-1480.

  13. Ebbert JO, Yang P, Vachon CM, Vierkant RA, Cerhan JR, Folsom AR, et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003;21(5):921-926.

  14. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-239.

  15. Arrieta O, Guzmán-de Alba E, Alba-López LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Invest Clin 2013;65 Suppl 1:S5-S84.

  16. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994;271(24):1940-1947.

  17. Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e61S-77S.

  18. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55.

  19. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e1S-29S.

  20. GdDF. Decreto por el que se expide el reglamento de la Ley de Protección a la Salud de los No Fumadores del Distrito Federal. México: Gaceta Oficial del Distrito Federal, 4 de abril 2008.

  21. Calleja N. Medidas para el control del tabaco en México y en el mundo. Enseñanza e Investigación en Psicología 2012;17(1):83-99.

  22. Arrieta O, Quintana-Carrillo RH, Ahumada-Curiel G, Corona-Cruz JF, Correa-Acevedo E, Zinser-Sierra J, et al. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico. Tob Induc Dis 2014;12(1):25.

  23. Pinsky PF, Kramer BS. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening. J Nat Cancer Inst 2015;107(11).

  24. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert opinion on therapeutic targets 2012;16(1):15-31.

  25. Shaw AT. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer. Clin Adv Hematol Oncol 2015;13(5):282-284.

  26. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455(7216):1069-1075.

  27. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6(2):201-205.

  28. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139.

  29. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500.

  30. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nat Acad Sci U S Am 2004;101(36):13306-13311.

  31. Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sanchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung cancer 2015;87(2):169-175.

  32. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol 2011;9(3):207-214.

  33. Pillai RN, Ramalingam SS. The biology and clinical features of nonsmall cell lung cancers with EML4-ALK translocation. Curr Oncol Rep 2012;14(2):105-110.

  34. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014;40(2):300-306.

  35. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-566.

  36. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, et al. FDA approval summary: crizotinib for the treatment of metastatic nonsmall cell lung cancer with anaplastic lymphoma kinase rearrangements. The oncologist 2014;19(10):e5-11.




2020     |     www.medigraphic.com